Our laboratory is at the forefront of viral vaccine research, striving to address global health challenges posed by emerging and re-emerging viral infections. We are working in the development of next-generation vaccine candidates, including DNA and RNA-based platforms, with a focus on combating viral diseases. Our research integrates innovative strategies, such as the use of molecular adjuvants and delivery systems, to enhance vaccine immunogenicity and efficacy. In addition to vaccine development, we investigate host immune responses to viral infections to uncover novel mechanisms of immune activation and regulation. Our multidisciplinary approach bridges basic immunology, virology, and translational research, aiming to contribute cutting-edge solutions for the prevention and control of viral infections.

Ubiquitination/deubiquitination is an important post-translational modification (PTM) that viruses exploit to enhance their replication, immune evasion and to manipulate host cellular mechanisms. The major enzymes involved in ubiquitin-proteasome system are ligases and deubiquitinases. Among deubiquitinases. Ubiquitin specific proteases (USPs) play a major role in virus transmission by modulating the expression of proteins involved in viral replication and propagation. Our research goal is also focused on the study of these PTMs in viral infection and their outcome.